ASCO 2023: AI-Derived Digital Patholo... - Advanced Prostate...
ASCO 2023: AI-Derived Digital Pathology Biomarker Predicts Benefit of Long-Term ADT with Radiotherapy in Localized High-Risk Prostate Cancer
Written by
zeitgeistxx
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Dad was on triple ADT for about 15 years, but his testosterone and PSA stayed down without the Lupron so he ended up only getting the lupron every 18 months or so. Whenever he got his Lupron shot his testosterone and PSA would spike for a while despite taking cassidex. There is an oral form of the injectable degarelix Firmagon that is a lot safer from a heart attack standpoint and doesn't cause the testosterone spikes, and you don't need the cassidex or the proscar. Unfortunately you can get androgen insensitivity sooner with it, but overall survival is better.
I was on Lupron for just 6 months when I had radiation in 2014 for recurrence after 2007 prostatectomy and it did cure me.
Not what you're looking for?
You may also like...
No Benefit With Longer Course of ADT in Localized, High-RiskProstate Cancer
renalandurologynews.com/home/conference-highlights/genitourinary-cancers-symposium/no-benefit-longer
Increased risk of dementia with ADT, especially Degarelix?
https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-prostate-cancer/144860-asco-2023-
Newly dx with high risk locally advanced prostate cancer..bewildered
just been dx with high risk locally advanced prostate cancer. Please see the profile for lots more...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
ensitive-prostate-cancer
More info:
https://www.urotoday.com/conference-highlights/asco-gu-2022/
Treatment Considerations for Prostate Cancer Progressing After Combination Therapy for mCSPC
treatments for metastatic PC....